HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $94 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained a $94 price target.
February 28, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytokinetics has been reiterated with a Buy rating and a $94 price target by HC Wainwright & Co. analyst Joseph Pantginis.
The reiteration of a Buy rating and maintenance of a high price target ($94) by a reputable analyst suggests a strong vote of confidence in Cytokinetics' potential. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100